The consortium aims to develop a “near-patient drug development” strategy that includes using 3D cell models comprised of patient-derived cells. The strategy will reduce clinical failures, enable the development of more effective treatments at a lower cost, and allow the right drug leads to be matched with the right patient subgroup.
Out of 934 applicants, Lucero was selected by Vinnova, Sweden’s Innovation Agency, as one of the recipients of the Innovative Startups Stage 1 grant. The grant is targeted towards early-stage startups that are based on innovative products and services and that show global growth potential. The money is meant to help startups develop their prototypes and business models, as well as create strategies to protect and commercialize their intellectual assets.
With the help of ACTPHAST4.0 partners, VUB B-PHOT Brussels Photonics and Vrije Universiteit Brussel, both world leaders in photonics education, research, and innovation, Lucero aims to optimize our optical setup to maximize its potential to work with 3D cell models, as well as to reduce the size of the system itself.
Lucero has been awarded Almi Företagspartner Väst’s verification grant to help fund prototype development that is set to begin this fall.
Lucero has joined the Gothenburg-based Chalmers Ventures’ Accelerator program. The Accelerator has been supporting great founders and startups since 1999 through mentoring, investment, and access to Chalmers Ventures’ broad network of professionals.
Lucero will participate in the X-Europe program this fall to further develop our product-market fit and find future corporate collaboration partners.
We are very honored and happy to share that from the hands of our great advisor Dr. Giovanni Volpe, Lucero was selected as one of only three projects from Sweden to receive the Proof of Concept Grant (PoC) from the European Research Council. This grant aims to explore the commercial and societal potential of the very best and most innovative research from the European Union.